The present observations raise the possibility of exploiting CLDN3 and CLDN4 as potential biomarkers for ovarian cancer progression and highlight maintenance of E-cadherin levels as a target for therapeutic intervention. This evidence concerns the gene CLDN4 and ovarian cancer.